中药注射剂辅助治疗非小细胞肺癌的临床疗效及经济学评价

Clinical efficacy and economic evaluation of Chinese medicine injection adjuvant therapy on non-small cell lung cancer

目的:分析中药注射剂辅助治疗非小细胞肺癌的临床疗效及药物经济学,探讨中药注射剂辅助治疗方案在非小细胞肺癌临床治疗中的应用价值。方法:选取2013年2月-2014年1月我院收治的92例非小细胞肺癌患者为观察对象,根据治疗方案分为观察组47例(中药注射剂辅助GP化疗),对照组45例(单纯GP治疗)。回顾性分析两组的临床疗效、不良反应、生活质量以及药物经济学评价的差异。结果:92例患者均顺利完成治疗,观察组患者总有效率为68.08%,与对照组无显著性差异(P>0.05)。但是观察组生活质量改善率为40.43%,显著高于对照组,不良反应发生率及C/E(369.80),显著低于对照组,P<0.05,差异具有显著性。结论:与单纯化疗相比较,中药注射剂辅助治疗非小细胞肺癌疗效显著,且更符合药物经济学要求,是较为安全、有效、经济的治疗方案。

Objective: To observe the effect of traditional Chinese medicine injection adjuvant therapy on non-small cell lung cancer and pharmacoeconomic analysis. Methods: All 92 cases of non- small cell lung cancer patients were divided into two groups,47 cases in observation group( TCM injections assist GP chemotherapy),45 cases in the control group( simple GP treatment). To analyze the clinical efficacy,adverse reactions,quality of life and pharmacoeconomic evaluation. Results: All 92 patients were successfully treated. Total effective rate was 68. 08%,and there was no significant difference( P > 0. 05) with the control group. Improvement rate of quality of life in observation group was 40. 43%,significantly higher than control group. The incidence of adverse reactions and C / E( 369. 80),were significantly lower than the control group( P < 0. 05),and the difference was significant. Conclusion: Compared with chemotherapy alone,TCM injections assisted treatment of non- small cell lung cancer is economic,relatively safe and effective.